STAT+: Eli Lilly to buy Orna Therapeutics for $2.4 billion

Eli Lilly has announced its acquisition of Orna Therapeutics for $2.4 billion. Orna Therapeutics is a biotechnology company based in Watertown that specializes in ‘in vivo’ CAR-T therapies aimed at treating autoimmune diseases. The acquisition reflects Eli Lilly's strategic interest in expanding its capabilities in the field of innovative therapies for complex health conditions. The deal is significant in the context of Eli Lilly's ongoing efforts to enhance its portfolio in the biotechnology sector. By acquiring Orna Therapeutics, Eli Lilly aims to leverage Orna's expertise and technology in CAR-T therapies, which are designed to modify a patient's own immune cells to better target and combat diseases. This approach is particularly relevant for autoimmune diseases, which can be challenging to treat with conventional methods. The acquisition is expected to bolster Eli Lilly's research and development initiatives, potentially leading to new treatment options for patients suffering from autoimmune conditions. The financial terms of the deal indicate a strong commitment from Eli Lilly to invest in the future of therapeutic innovations that could significantly impact patient care. Overall, this acquisition marks a notable development in the biotechnology landscape, highlighting Eli Lilly's proactive approach to enhancing its therapeutic offerings through strategic partnerships and acquisitions.